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Abstract: Cardiovascular diseases, chronic obstructive pulmonary diseases, diabetes, rheumatoid
arthritis, and cancer are the most common noncommunicable diseases (NCDs). These NCDs share
risk factors with periodontal disease (PD), a preventable risk factor linked to lifestyle. The discussion
regarding the association between these chronic diseases is more complex. There is still a significant
knowledge gap particularly of the causal relationship between PD and NCDs. In this paper, we present
fundamental knowledge of the mechanisms and roles of putative periodontal bacteria to gather
several hypotheses, evidence that clinical studies thus far have not produced. Although the causal
hypotheses are not yet clearly established on a biological basis, prevention and prophylactic measures
are recommended to prevent even the possibility of such potential risk factors.
Keywords: noncommunicable disease; periodontal disease; periodontal bacteria; cancer; cardiovascular
diseases; diabetes; pulmonary diseases; rheumatoid arthritis
1. Introduction
The Sixtieth World Health Assembly (WHA60.17) highlighted in 2007 the link between oral health,
general health and the quality of life. It explained that the prevention and treatment of chronic diseases
requires the establishment of prevention programs for oral disease and oral health promotion [1]. This
assembly, with the support of the World Dental Federation, advocated for member states to introduce
rules promoting oral health directly into their policies for the treatment and prevention of chronic
noncommunicable and communicable diseases [2–4].
Cardiovascular diseases, chronic obstructive pulmonary diseases, rheumatoid arthritis, diabetes,
and cancer are the most common noncommunicable diseases (NCDs). These NCDs and periodontal
disease (PD) have identical but preventable risk factors linked to lifestyle [5]. Thus, the link between
several oral diseases and NCDs is due to the fact that these diseases share risk factors [6]. Many
general pathologies are characterized by oral manifestations, which increases the risk of oral pathology.
Conversely, oral diseases are a risk factor for general pathologies. This approach, based on common
determinants, has received significant support from research and evidence-based approaches. If the
concept of common risk factors is indisputable, the interrelationship between oral diseases and NCDs
is proven by evidence [7].
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The oral cavity of humans contains more than 700 bacterial species that are able to penetrate the
digestive and respiratory tracts [8]. The oral microbiota is a key factor in the protection against the
colonization of extrinsic pathogens that could impact systemic health [9]. However, the imbalance
of the ecosystem, which can be caused by a weak immune system, leads to a challenge for oral and
systemic health. The ecological conditions of these habitats are constantly changing, so ecosystems are
subject to frequent variations.
The oral microbiome is a key factor in health or disease [10]. Its modification contributes to oral
and systematic diseases [11]. Moreover, dysbiosis of the oral ecosystem is associated with systemic
diseases, such as cardiovascular diseases, cancers, and diabetes [12].
A systematic literature search was conducted, fulfilling PRISMA criteria (Preferred Reporting Items
for Systematic reviews and Meta-analyses). Electronic research was organized in Pubmed, Embase,
and Cochrane databases. No language filters were implemented. The research was performed from
2000 to April 2019. The following MeSH and non-MeSH search terms were used in order to encompass
every type of periodontal pathogens and cardiovascular diseases, diabetes, rheumatoid arthritis, cancer,
and chronic obstructive pulmonary disease: (“periodontitis”[MeSH Terms] OR “periodontitis”[All
Fields]) AND (“Pathogens”[Journal] OR “pathogens”[All Fields]) AND (“diabetes mellitus”[MeSH
Terms] OR (“diabetes”[All Fields] AND “mellitus”[All Fields]) OR “diabetes mellitus”[All Fields]
OR “diabetes”[All Fields] OR “diabetes insipidus”[MeSH Terms] OR (“diabetes”[All Fields] AND
“insipidus”[All Fields]) OR “diabetes insipidus”[All Fields]) AND (“cardiovascular diseases”[MeSH
Terms] OR (“cardiovascular”[All Fields] AND “diseases”[All Fields]) OR “cardiovascular diseases”[All
Fields]) AND (“arthritis, rheumatoid”[MeSH Terms] OR (“arthritis”[All Fields] AND “rheumatoid”[All
Fields]) OR “rheumatoid arthritis”[All Fields] OR (“rheumatoid”[All Fields] AND “arthritis”[All
Fields])) AND (“neoplasms”[MeSH Terms] OR “neoplasms”[All Fields] OR “cancer”[All Fields])
AND (“pulmonary disease, chronic obstructive”[MeSH Terms] OR (“pulmonary”[All Fields] AND
“disease”[All Fields] AND “chronic”[All Fields] AND “obstructive”[All Fields]) OR “chronic obstructive
pulmonary disease”[All Fields] OR (“chronic”[All Fields] AND “obstructive”[All Fields] AND
“pulmonary”[All Fields] AND “disease”[All Fields]). The selection procedure was performed by two
reviewers, who evaluated the titles and abstracts of the articles identified in the electronic databases.
Finally, 98 studies were included in this review.
In this review, fundamental knowledge of the mechanisms and roles of putative periodontal
bacteria on the potential development of the five main noncommunicable diseases—cancer,
cardiovascular diseases, diabetes, pulmonary diseases, rheumatoid arthritis—are presented.
2. Periodontal Disease
Periodontal disease (PD), classified by the World Health Organization (WHO) as a
noncommunicable disease (ICD-10, K.053), is a microbe-induced inflammatory and multifactorial
chronic immunologic disease [13]. Periodontitis is a polymicrobial infection due to an increase
in pathobionts within the microbiota [14]. The initially synergistic microbiota gradually becomes
dysbiotic [15]. Bacterial accumulation around the tooth on gingival or subgingival level gives rise
to an inflammatory response in the tissues surrounding the teeth. The inflammation of the gum
leads to the destruction of the alveolar bone and loss of gingival attachment to the teeth. PD is a
progressive disease that ranges from gingivitis (reversible inflammation) to periodontitis (irreversible
inflammation). The evolution of PD is correlated with several modifiable and unmodifiable risk
factors [16]. PD has been the subject of many studies for many years within the scientific community
that aimed to identify the links that may exist among systemic diseases [17]. Several bacterial species
associated with periodontitis have been suggested to be involved in the pathogenesis of some systemic
diseases [18]. However, because of the complexity of these periodontal-systemic associations and
conflicting scientific reports, most of the associations remain speculative [19].
Periodontopathogenic bacteria according to their pathogenicity and properties are organized
into complexes that are closely interrelated [20]. The bacteria from the green, purple, and yellow
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complexes are named “early colonizers” because they are able to adhere to the pellicle. The orange
complex comprises putative periodontal pathogens, such as Fusobacterium nucleatum (F. nucleatum),
that generally appear after the early colonizers are established [21]. These bacteria, classified as
moderately pathogenic, associate with other periodontal bacteria to form the basis for the colonization
of the sulcus. The highly pathogenic bacteria of the red complex, which include Porphyromonas
gingivalis (P. gingivalis), Treponema denticola (T. denticola), and Tannerella forsythia (T. forsythia), are the
most important pathogens in adult PD [22]. The recent “Keystone-Pathogen Hypothesis” (KPH)
considers that certain bacteria in low quantities, such as P. gingivalis, can act on the host immune
system and convert the microbiota from symbiotic to dysbiotic to provoke inflammatory disease [16].
The host immune system could be modified. In fact, P. gingivalis could act on the immune system of
the host in three different ways. This pathogen may alter the Toll-like receptor (TLR) response, subvert
interleukin-8 (IL-8), or alter the complement system [23,24]. First, during inflammatory process, P.
gingivalis lipopolysaccharide (LPS) expression increases which reduces the TLR4 response and could
facilitate survival and multiplication of the entire microbial community [25]. Then, P. gingivalis can
block production of IL-8, which is produced by gingival epithelial cells in response to other bacteria,
by secreting a serine phosphatase that inhibits the synthesis of IL-8 [26]. This process delays the
recruitment of neutrophils and could facilitate initial microbial colonization of the periodontium [27].
Other bacteria from the red complex such as T. denticola, are also able to manipulate the IL-8 response
of the host [28]. Finally, P. gingivalis is able to avoid complement-mediated detection by producing
gingipains (membrane bound and soluble arginine-specific cysteine proteinases). Gingipains cleave
complement factors C3 and C5 into active fragments C5a (cell activator) and C3b (phagocytosis
enhancer) and degrade them [29]. The increasing of C5a leads to an increased activation of the C5a
receptor on leukocytes [29]. C5a receptor is involved in crosstalk with TLR2, which is activated in
parallel by P. gingivalis surface ligands. While this crosstalk leads to increased inflammation, it impairs
the killing capacity for leukocytes [30].
The pathogenicity of these bacteria is significantly increased following the production of various
enzymes and toxins. The attachment loss and an increase in pocket depth are due to bacteria belonging
to the orange complex. Through their metabolism, these bacteria also create living conditions for red
complex bacteria that are strict anaerobes and thus allow them to colonize the sulcus. The presence of
bacteria from the red complex and the Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans)
complex is the witness of the final colonization phase. The pathogenesis of PD results from the complex
interaction between periodontal pathogens and the host immune response, controlled by environmental
and genetic factors. Another concept named the “ecological plaque hypothesis” considers that groups
of bacteria, such as the bacteria from the red complex, can create an ecosystem capable of inducing
periodontal disease [31]. The pathogenesis of PD could be the result of a dysbiosis in the microbiota
caused by ecological stress due to the enrichment of several pathogens [30].
Therefore, the inflammation and tissue destruction in the case of periodontitis is not only due to
the presence of some periodontopathogens such as bacteria from the red complex but to the dysbiosis
of the oral microbiota that they induce [32].
3. The Invasion Process by Periodontal Bacteria
Oral bacteria, bacterial products, and inflammatory molecules can invade the human body in two
main ways: (i) the bloodstream or (ii) the digestive tract (Figure 1).
First, bloodstream invasion is possible because anatomically, the periodontal pockets are close to
the bloodstream. Their contents (periodontal bacteria, bacterial products, immunocomplexes, and
mediators of inflammation) will therefore be able to diffuse and reach different sites of the human
body [33]. Periodontal pathogenic bacteria that have the property of being mobile will be able to
migrate and invade the epithelium and then the connective tissue [34] before reaching the bloodstream.
In patients with periodontitis, gingival ulceration is the major cause of bacteremia. Bacterial products
such as exotoxins and endotoxins are also able to reach the bloodstream and thus diffuse to exert
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their toxicity at a distance. Thus, endotoxins are lipopolysaccharides of the outer membrane of
Gram-negative bacterial cells responsible for numerous pathologies [35]. Pro-inflammatory molecules
such as interleukin (IL) 1β, IL-6, or tumor necrosis factor (TNF) will reach the systemic circulation,
triggering a response in other tissues such as the liver [36].
Finally, by alimentary dissemination, oral bacteria, bacterial products, and inflammatory molecules,
reach the digestive tract including the stomach. During digestion, the oral bacteria will migrate into
the stomach. Only those that resist the acidic pH of the stomach will survive and multiply in the
gastrointestinal tract [37,38]. Thus, the oral microbiota and the microbiota of the large intestine have
similarities in 45% of subjects with PD [39]. Previous studies demonstrated that the modification of the
oral microbiota due to oral disease is linked to the dysbiosis of the gut microbiota [40]. This correlation
between the oral microbiota and the intestinal microbiota is due to daily activities (e.g., swallowing)
that promote the transport of bacteria from the oral cavity to the gastrointestinal tract. However, the
precise mechanism of invasion must be determined [41].
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4. Periodontal Pathogens and Diabetes
Diabetes has a dual association with PD [42]. Identified as chronic pandemic diseases, PD and type
2 diabetes (T2DM) are also risk factors for cardiovascular complications [43]. The hypothesis of a causal
relationship between the imbalance of the periodontal microbiota and the incidence of metabolism
disease is advanced [44]. Periodontal infection and subsequent inflammation increase insulin resistance
and negatively affect glycemic control. This is partly explained by the increase in the level of systemic
pro-inflammatory mediators—cytokines in particular, which exacerbate insulin resistance—and by the
chronic bacteremia that accompanies periodontitis. In the case of PD, several inflammatory molecules,
such as IL-1β, IL-6, IL-8, LPS, TNF-α, and prostaglandin (PG) E2, are liberated. These molecules are
able to interact with free fatty acids, lipids, and advanced glycation end products, all of which are
characteristic of diabetes. Thus, some intracellular pathways associated with insulin resistance are
impacted, such as the I-kappa-B (IκB), I-kappa-B kinase-β (IKKβ), nuclear factor-kappa B (NF-κB), and
the protein c-Jun N-terminal kinase (JNK) axes. JNK promotes insulin resistance by phosphorylating
serine residues in the insulin receptor substrate-1. The counter-regulatory phosphorylation of serine
and threonine inhibits the insulin receptor signaling that normally occurs through a tyrosine kinase
cascade. Concerning IKKβ, the insulin resistance results from the activation of NF-κB transcription.
Activation of IKKβ leads to the phosphorylation of IκB, a cytosolic inhibitor of NF-κB. Phosphorylation
by IKKβ targets IκBα for proteasomal degradation, which liberates NF-κB for translocation into the
nucleus, where it initiates the transcription of various genes involved in insulin resistance, such as
growth factors, cytokine genes (IL-1, IL-6, IL-8, and TNF-α), adhesion molecules, and proteins in
the acute phase. The activation of these inflammatory pathways in hepatocytes, endothelium cells,
immune cells (monocytes or macrophages), muscle cells, and adipocytes promotes and contributes to
an increase in overall insulin resistance, which makes it difficult to perform metabolic regulation in
individuals with both PD and T2DM [45].
The consequences of periodontal microbiota disbalance were also significant at the systemic
level, with metabolic modifications connected to diabetes [46]. Additionally, a discordance in the
microbial profile between chronic periodontitis patients with and without T2DM has been emphasized.
The strength of evidence is robust for T. forthysia, which is related to being less frequent in the
T2DM-PD group, followed by the lowest evidence for other pathogens such as Aggregatibacter
actinomycetemcomitans and P. gingivalis [47] (Figure 2).
The role of oral bacteria in adiposity was also demonstrated. Selenomonas noxia (S. noxia) represented
more than 1.05% of the total bacterial in 98.4% of overweight women [48]. S. noxia could be a predictive
marker of obesity given its sensitivity and specificity. This leads to the relevant hypothesis of whether
the bacteria of the oral sphere are implicated in the process that is likely to lead to obesity. The role of
periodontopathogenic bacteria in this pathology is yet to be established. However, animal studies have
demonstrated that the modification of the intestinal microbiota by taking specific nutrients, prebiotics,
or natural antibiotics could modify satiety and insulin resistance and thus allow better control of
diabetes [49,50].
Microorganisms 2019, 7, 424 6 of 17
Microorganisms 2019, 7, x FOR PEER REVIEW 6 of 17 
 
 
 
 
Figure 2. Periodontal pathogens implicated in the most common noncommunicable diseases. The 
colors in boxes refer to (i) the colors of the Socransky complexes for the purple, green, yellow, orange, 
and red colors, and (ii) other periodontal bacteria for the gray color. A. actinomycetemcomitans: 
Aggregatibacter actinomycetemcomitans; C. morbi: Cantonella morbi; D. wimpennyi: Dysgonomonas 
wimpennyi; F. nucleatum: Fusobacterium nucleatum; H. pylori: Helicobacter pylori; P. gingivalis: 
Porphyromonas gingivalis; S. noxia: Selenomonas noxia; S. sanguinis: Streptococcus sanguinis; T. denticola: 
Treponema denticola; T. forsythia: Tannerella forsythia. 
5. Periodontal Pathogens and Cardiovascular Diseases 
The hypotheses from the literature strongly argue for an increased impact of long-term 
periodontitis on the main noncommunicable diseases. 
Periodontal infections are strongly associated with the development of atherosclerosis [51]. The 
systemic inflammatory or immune response to periodontal infection may increase cardiovascular 
Noncommunicable
Diseases
Chronic obstructive 
pulmonary diseases
P. gingivalis
Streptococcus
Fusobacteria
Prevotella (P. intermedia, P. endodontalis)
Eikenella Veillonella
C. morbi
D. wimpennyi
Gemella
Olsenella
Pseudomonas
Rheumatoid arthritis
P. gingivalis
A. actinomycetemcomitans
F. nucleatum
Cancer
P. gingivalis
T. forsythia
T. denticola
H. pylori
F. nucleatum
A. actinomycetemcomitans
Diabetes
P. gingivalis
T. forsythia
S. noxia
A. actinomycetemcomitans
Cardiovascular diseases
P. gingivalis
T. forsythia
T. denticola
A. aphrophylus
Viridans streptococci
(S. sanguinis)
A. actinomycetemcomitans
Figure 2. Periodontal pathogens implicated in the most common noncommunicable diseases. The colors
in boxes refer to (i) the colors of the Socransky complexes for the purple, green, yellow, orange, and red
colors, and (ii) other periodontal bacteria for the gray color. A. actinomycetemcomitans: Aggregatibacter
actinomycetemcomitans; C. morbi: Cantonella morbi; D. wimpennyi: Dysgonomonas wimpennyi; F. nucleatum:
Fusobacterium nucleatum; H. pylori: Helicobacter pylori; P. gingivalis: Porphyromonas gingivalis; S. noxia:
Selen onas noxia; S. sa guinis: Streptococcus sangui is; T. denticola: Trepo ema denticola; T. forsythia:
Tannerella forsythia
5. Periodontal Pathogens and Cardiovascular Diseases
The hypotheses from the literature strongly argue for an increased impact of long-term periodontitis
on the main noncommunicable diseases.
Periodontal infections are strongly associated with the development of atherosclerosis [51].
The systemic inflammatory or immune response to periodontal infection may increase cardiovascular
risk. Additionally, pathogens from the mouth can cross the gingival epithelio-conjunctive barrier as
well as the vascular endothelium and enter atherosclerotic plaques via the bloodstream, which could
promote an inflammatory or immune response within the atherosclerotic plaque [52].
According to Aarabi and colleagues, four different mechanisms could explain the link between
oral disease and the pathological process of atherosclerosis. First, an oral bacterium reaches the
bloodstream following bacteremia. Second, during an oral disease, mediators of inflammation are
released and can enter the bloodstream. Third, following exposure to components of oral pathogenic
bacteria, an autoimmune reaction against host proteins occurs. Finally, some oral pathogens produce
toxins with pro-atherogenic action [53].
P. gingivalis can intensify atherosclerosis after oral-hematogenous spread due to bacteremia.
In its presence, endothelial cells activate certain adhesion molecules, thus increasing the likelihood of
macrophage diapedesis and the subsequent conversion to foam cells and further atheroma progression.
PGE2, TNF-α, and IL-1b produced locally at the periodontal pockets in response to PD bacteria will
end up in the bloodstream, causing a disproportionate increase in the local tissue innate immune
response. However, the mechanism of the active invasion of endothelial cells by P. gingivalis, likely to
adjust the inflammatory response of these cells, remains unclear [54,55].
The association of coronary heart disease and PD may be due to a trait underlying response,
which puts a person at high risk of codeveloping periodontal diseases and coronary artery disease.
Once established, PD provides a bioburden of endotoxin (lipopolysaccharide) and inflammatory
cytokines, especially thromboxane A2, PGE2, IL-1α, and TNF-β, which serve to initiate and exacerbate
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atherogenesis and thromboembolic events [56]. In atherosclerotic plaques, various periodontal bacteria
have been identified [57]. Moreover, in mouse models, P. gingivalis increases the progression of
inflammatory plaque accumulation in the innominate arteries with the accumulation of inflammatory
mediators and cholesterol esters [58]. Serum IgA antibodies to P. gingivalis are significantly higher in
Chinese patients with myocardial infarct [59].
PD is correlated with an increased risk of future myocardial infarction. However, a recent
meta-analysis from observational studies could not establish a causative relationship between PD and
myocardial infarction. Additional investigations are recommended [60]. Analysis of thrombi collected
by aspiration during interventions on the coronary arteries of patients who had a myocardial infarction
showed 19.7% A. actinomycetemcomitans, 3.4% P. gingivalis, and 2.3% T. denticola [61]. Antibody levels
against four major periodontal pathogens, P. gingivalis, A. actinomycetemcomitans, T. forsythia, and
T. denticola, are related to an increased relative risk of myocardial infarction [62] (Figure 2). Other
studies highlight the important role of oral Viridans streptococci in the development of myocardial
infarction [63–65].
Infection with P. gingivalis after myocardial infarction in mice enhanced myocardial high mobility
group box 1 (HMGB1) expression. HMGB1 is a nuclear protein released from necrotic cells and capable
of inducing the inflammatory response. There is a possible relationship between PD and postinfarction
myocardial inflammation through HMGB-1 [66].
Infection with P. gingivalis during myocardial infarction generates a prejudicial part in the
recuperation procedure of the infarcted myocardium by penetration and invasion of P. gingivalis into
the myocardium, thus favoring programmed cell death and the matrix metalloproteinase (MMP) 9
action of the myocardium, which successively produces cardiac rupture [67].
Clinical studies particularly suggest a direct relationship between the severity of periodontal
conditions and left ventricular hypertrophy. In animal transverse aortic constriction models,
A. actinomycetemcomitans, a Gram-negative bacterium that is considered an etiologic agent in
endocarditis, clearly improved cardiac hypertrophy with matrix MMP-2 activation [68].
Control of chronic inflammation caused by periodontitis may positively impact the treatment of
myocardial hypertrophy, decreasing the risk of acute myocardial infarction [69].
The risk of stroke, described by a meta-analysis of cohort studies, was significantly increased by
the presence of periodontitis [70]. PD was significantly correlated with cardioembolic and thrombotic
stroke subtypes. Regular dental care utilization was associated with a lower adjusted stroke risk [71].
Pussinen and colleagues have established that P. gingivalis, a Gram-negative anaerobic bacterium,
may especially be correlated with stroke [72].
Experimental rats with periodontitis and stroke may have impaired endothelial function in
gingival tissues. These studies show that the disruption of vascular function in oral microcirculation
may be generated by the fundamental interaction between the oxidative stress induced by PD and
nitric oxide, similar to the interactions existing in stroke cases [73]. Reducing the risk of stroke
therefore requires the management of PD. It also involves daily individual prophylaxis of oral health,
whose purpose is the disruption and removal of the biofilm. It is necessary to control the risk of
chronic inflammation, which can lead to tragic consequences such as stroke [74]. These are arguments,
as recommended by the WHO, for developing intersectoral approaches to chronic disease control in an
alliance of general practitioners, dentists, nurses, and specialists [75].
A. actinomycetemcomitans and Aggregatibacter aphrophilus belong to the HACEK (Haemophilus,
Aggregatibacter, Cardiobacterium, Eikenella, Kingella) group of Gram-negative bacteria, a recognized
cause of infective endocarditis (Figure 2). HACEK organisms are a part of the normal microbiota
of the oral and upper respiratory tract in humans. However, these bacteria are implicated in 1% to
3% of all infective endocarditis [76]. A. actinomycetemcomitans is also implicated in the etiology of
aggressive periodontitis and generates many virulence factors, such as leukotoxin (repeats-in-toxin
protein), which kills human immune cells [77,78].
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Streptococcus sanguinis (S. sanguinis), a commensal bacterium, profuse in periodontitis, is recognized
as an origin of infective endocarditis [79]. Its fimbriae and adhesin facilitate its initial attachment on
the tooth. Then, the production of glucans and eDNA promotes the maturation of S. sanguinis biofilm.
After accessing the heart, S. sanguinis must then adhere to the endocardium. Considering the impact
of biofilm formation on adhesion in the oral cavity, it would be conceivable that biofilm formation
might be significant for adhesion to endocardial surfaces as well. Indeed, endocarditis is frequently
regarded as a model of a biofilm-mediated disease [80,81]. However, studies have demonstrated that
S. sanguinis endocarditis causation is not dependent upon biofilm formation [79]. Therefore, in contrast
to this situation in the oral cavity, there is as yet no evidence that biofilm formation is important for
S. sanguinis in the cardiac environment in relation to infective endocarditis [79].
6. Periodontal Pathogens and Chronic Obstructive Pulmonary Disease
While respiratory diseases are among the leading causes of death in the world, tobacco is the major
risk factor [82]. Nearly half of all chronic obstructive pulmonary disease (COPD) deaths are attributable
to smoking; 80–90 % of cases of COPD can be avoided by refusing tobacco [83,84]. Periodontal
pathogens and inflammatory cytokines can generate systemic inflammation, which can take part in
the pathogenesis of chronic obstructive pulmonary disease (COPD) [85]. There are similarities in
the disease mechanisms—sustained neutrophil inflammation, dysfunctional neutrophil behaviors,
and connective tissue loss—that imply a common pathophysiology and confirms the association in
clinical evidence that resulted from the meta-analyses [86].
The processes that are suggested to associate periodontal diseases and COPD include the overspill
of topically generated inflammatory mediators into the systemic circulation or bacteremia of oral or
pulmonary origin that accelerates acute response, mechanical aspiration of oral content in the tree
respiratory, and reactive oxygen species and cytokines released by systemic neutrophils at distant
sites [85]. Oral symbiosis requires professional management and regular visits to reduce the virulent
bacterial load, and consequently, a reduction in the incidence or severity of the COPD occurs. Daily
individual oral hygiene is a major factor that decreases the risk of disease among subjects with
respiratory illness [87].
The PD and COPD association do not necessarily require bacterial aspiration through the
respiratory tract. Local cytokines and other active molecules produced by periodontal inflammation
penetrate into the systemic circulation. The endothelium and circulating immune cells are thus
activated. Both contribute to the inflammatory burden by the liberation of activated and destructive
mediators. This process also takes place in the lungs, initiating pulmonary inflammation. Periodontal
bacteria move in gingival vasculature via microulcerations in the epithelium, permitting hematogenous
dispersion of bacteria and inflammatory mediators [88].
Among the oral bacterial species involved in bronchopulmonary pathologies, Streptococcus,
Veillonella, Gemella, Porphyromonas, Olsenella, and Eikenella were found [89] (Figure 2). Identified
in several studies, Fusobacteria, Pseudomonas, Prevotella, and Streptococcus make up the pulmonary
microbiome of COPD [90] (Figure 2). Both chronic periodontitis and COPD are associated with an
increase in P. intermedia, Catonella morbi, Dysgonomonas wimpennyi, and Porphyromonas endodontalis as
well in the genera Dysgonomonas, Desulfobulbus, and Catonellas. Thus, active care of periodontitis, with
the goal of reducing virulent bacteria, should have a direct impact and benefit on COPD subjects.
However, more longitudinal studies are required to validate this hypothesis [91].
7. Periodontal Pathogens and Rheumatoid Arthritis
Strong epidemiological, serological, and clinical associations have been observed between
rheumatoid arthritis (RA) and periodontitis [92]. The presence of PD might contribute to the
progression of RA, while RA might have little effect on accelerating the development of PD. RA and
periodontitis share many common pathological features, such as chronic inflammation induced by
pro-inflammatory cytokines, connective tissue breakdown, and bone erosion [93]. Mutual in both
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diseases, there is a growing diversity of MMPs and cytokines. However, despite this evidence showing
a link between rheumatoid arthritis and periodontitis, the exact mechanisms involving this association
have not been fully elucidated [94].
The periodontal pathogen A. actinomycetemcomitans has been recognized as a bacterial trigger for
RA, providing a link between autoimmunity and periodontal diseases. Indeed, the oral pathogens
may trigger the production of disease-specific autoantibodies and arthritis in susceptible individuals.
Periodontitis is characterized by the presence of citrullinated autoantigens that are primary immune
targets in RA. A. actinomycetemcomitans provokes activation of the citrullinating-enzyme process in
neutrophils and thus autoantigen output [95,96].
Most of the studies have shown the presence of oral bacteria in patients with RA,
highlighting P. gingivalis and F. nucleatum [97] (Figure 2). Some periodontal pathogens, such as
A. actinomycetemcomitans and P. gingivalis, may take part in RA autoantibody production through
direct posttranslational alteration of proteins or indirectly through impacting neutrophil-mediated
neo-epitope generation. P. gingivalis is often found in the synovial joints of RA. F. nucleatum has been
detected in synovial fluid and in plaque samples of patients with joint pathologies [98]. Periodontal
bacteria that overrun the bloodstream may also take part in chronic inflammatory reactions and the
production of antibodies [99].
Hypotheses have suggested that chronic periodontitis generates local and constant high levels
of microparticles that spread into the bloodstream and are considered inflammatory biomarkers or
mediators responsible for distant cell signaling and regulation [100]. It could establish a demonstration
of the increased risk for chronic disease in adults with PD [51]. It is now validated that the association
between infectious pathogens and autoimmune arthritis is more complicated than the one pathogen-one
disease process that consolidates the conceptual frame for Koch’s postulates. Immuno-pathological
similarities between these two conditions induce a greater risk for patients with periodontitis to
develop RA [101,102].
A better quality of life for patients with RA requires consideration of the inflammatory process of
periodontal disease with care to prevent, reduce, or cure periodontitis [103,104]. Reduced systemic
inflammation might contribute to a better clinical outcome of RA [93].
8. Periodontal Pathogens and Cancer
The human microbiota may play a role in carcinogenesis. At this time, biological hypotheses and
animal and human studies data corroborate the significant associations between PD and pancreatic,
neck, and head cancers and the risk of lung cancer [105]. Large cohort studies validated by meta-analyses
confirm the evidence of some positive associations between PD and total cancer risk, particularly for
head and neck, pancreas, and lung cancers. Unfortunately, the dispersion of the clinical parameters
used for the definition of periodontitis and the difficulties of adjustment for smoking status, lacking in
some studies, penalize the impact of the results of eligible studies for meta-analyses [105].
The biological hypothesis for the relationship between PD and carcinogenesis includes chronic
inflammation, attendance of periodontal pathogens, and a reservoir for potential carcinogenic
factors (e.g., Human papillomavirus). As specified by Mantovani and colleagues, nonsteroidal
anti-inflammatory medication decreases the incidence of certain cancer categories while reducing
mortality [106]. Furthermore, in experimental animal models, inflammatory cells, cytokines, and
chemokines are present in the microenvironment of all tumors, and in humans, inflammatory cells,
cytokines, and chemokines are present from the early stages of tumor development; the overexpression
of inflammatory cytokines may promote tumor development.
Smoking and alcohol consumption, which are clearly identified risk factors, can be considered
classic confounders. However, after adjustment, the association of causality between periodontitis
and the risk of oral cancers and/or oropharynx remains significant [93,107]. P. gingivalis infects the
epithelium of the esophagus of esophageal squamous cell carcinoma (ESCC) subjects, which establishes
a relationship between infection with P. gingivalis and the progression of ESCC and proposes that
Microorganisms 2019, 7, 424 10 of 17
P. gingivalis infection could be a biomarker for this disease [108]. In this context, the eradication of
virulent periodontal bacteria, common to PD and ESCC, could probably contribute to reducing the
global burden of these cancers [109].
The association between periodontitis and pancreatic cancer (PC) is well documented in the
literature. These are targeted studies of periodontal bacteria that may play a key role in the pathogenesis
of PC [110]. A current cohort survey, using direct bacterial DNA quantification from the saliva of
subjects recovering years prior to diagnosis, identified associations between A. actinomycetemcomitans,
P. gingivalis, and pancreatic cancer [111,112] (Figure 2). F. nucleatum, a member of the orange complex,
has been associated in many studies with colorectal cancer [113]. However, it is uncertain whether this
pathogen is identified at higher levels in the bowel as an outcome of periodontitis.
The dysbiosis of the periodontal microbiota is associated with several chronic diseases, such as
gastrointestinal system diseases. Inflammatory bowel disease was one of the first to be highlighted.
Scientific advances have increased the level of correlation evidence between PD and gastrointestinal
cancers and liver cirrhosis [11]. The risk of developing precancerous gastric lesions is increased in the
presence of potentially virulent periodontal factors and with the complex and diverse nature of the
oral microbiota [114]. In periodontitis, significant levels of the colonization of pathogens, members
of the red complex of Socransky, and A. actinomycetemcomitans, are correlated with an increased risk
of gastric precancerous lesions. An increase in the DNA of selected bacteria (P. gingivalis, T. forsythia,
T. denticola, and A. actinomycetemcomitans) is associated with increased levels of PD indices [115].
The most significant risk component of noncardiac gastric cancer, found in all other areas of the
stomach other than the upper stomach, is Helicobacter pylori (H. pylori), potentially present in the oral
microbiome (e.g., saliva and dental plaque). The pathogen may be dissolved orally. The infection
rate is essentially a function of hygiene condition as well as the degree of antibiotic use [116–119].
Initial results from clinical trials have shown that H. pylori-positive dyspeptic patients may benefit
from periodontal therapy.
Knowledge of the processes of H. pylori-induced carcinogenesis remains limited, although
inflammation is a frequently cited hypothesis. Inflammation could be responsible for cancer by
increasing the production of free radicals, increasing apoptotic and necrotic epithelial cell death and
augmenting cell proliferation [120]. With this hypothesis, the validation of a relationship between
H. pylori and gastric cancer has led to a better understanding of the gastrointestinal microbiome and
novel strategies for the prevention of individual gastric cancer [121]. H. pylori is closely associated
with periodontitis with the potential to adhere to certain orange and red complex bacteria, such as
Fusobacterium species (F. nucleatum), P. gingivalis, and T. forsythia [122,123]. As the amount of these
pathogens is increased in periodontitis, it is more probable that mature biofilm may shelter H. pylori by
interacting with these bacterial species [58].
The evidence of the existence of the same H. pylori strain in plaque and stomach samples may
clarify the role of dental plaque as a sanctuary site for H. pylori and as a source of reinfection after
eradication, which is more difficult to eradicate from plaque than from the stomach [124].
9. Conclusions
This paper alone cannot answer the question of the causal link between periodontal bacteria and
the main noncommunicable diseases that are CVD, diabetes, RA, cancer, and COPD.
There is, however, some hypotheses that periodontal pathogens contribute to the increased
risk of NCDs by marginalizing the impact of conventional risk factors such as tobacco use, alcohol,
and physical inactivity. The effect of periodontal bacteria on NCDs briefly introduces the putative
biological mechanisms involved. Virulent periodontal bacteria almost all have a role in pathogenesis.
P. gingivalis is the typical example.
Some essential science of the processes and pivotal role of P. gingivalis incursion in arterial-
cardiovascular disease and cardiovascular cells has been demonstrated. S. sanguinis is well known
for its role in respiratory diseases and infective endocarditis. In addition, the potential interaction
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mechanisms described in immunology and molecular biology argue in favor of a potential causality. It
is well recognized that the homeostasis of oral microbiome communities is absolutely connected with
health factors.
Is the systematic care management of periodontitis indicated to reduce the risk of NCDs? Yes,
since by definition any management of PD must be beneficial. Then, there is a convergent web of
scientific information in favor of a possible causality. The insufficiency of proof that the treatment
of periodontal disease reduces the risk of major adverse NCD events is admissible. For this, large
randomized clinical trials are needed. Why has this not been done for 20 years? How long should
this be delayed? Between theory and practice, you have to decide. The decision maker must receive
specific advice from the scientific community. It is up to us to assess the risk. It should not be neglected
and taken into consideration. The insufficient evidence does not compensate for absence of evidence.
The methodological difficulties related to the epidemiological study of cohorts, long term, strongly
penalize the validation of hypotheses.
Although the association is not fully established and the biological mechanisms are not yet fully
understood, there is an obligation of precautionary principles and preventive measures to reduce
any potential risk factors. An integrated and collaborative approach to fight common risk factors,
as recommended by the WHO, for periodontal disease and chronic diseases is justified. It is important
to understand that PD is preventable. A potential gain in oral health from a reduction in a virulent
bacterial load can have direct or indirect positive effects on general health and even prevent the
possibility of such an association. At least establishing individual prophylaxis in adolescents and
young adults, including interdental hygiene, to promote a symbiotic periodontal microbiota throughout
their lives, as adequacy in their oral environments remains the highest priority.
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